GINA 2026 – Key Highlights

Global Strategy for Asthma Management & Prevention

Mission & Objectives

• Developed by the Global Initiative for Asthma (GINA) to provide evidence-based recommendations for asthma diagnosis, treatment, and prevention.
• Focuses on:
  • Achieving optimal symptom control.
  • Preventing severe exacerbations, lung function decline, and medication-related adverse effects.
  • Improving global access to essential inhaled therapies, particularly low-dose ICS–formoterol, to reduce preventable asthma deaths.

Major Updates in GINA 2026

1. Acute Asthma Management

Standardized Clinical Flowcharts

• Four evidence-based flowcharts for adults and children.
• Clear classification:
  • Mild
  • Moderate
  • Severe
  • Life-threatening asthma

Pediatric Assessment

• Recommend validated severity scoring systems such as PRAM (Pediatric Respiratory Assessment Measure).

Asthma with Anaphylaxis

• Administer intramuscular epinephrine immediately before bronchodilator therapy when both conditions coexist.

Oxygen Therapy

• Start supplemental oxygen only when:
  • SpO₂ <92%
• Oxygen targets:
  • Adults & older children: ≤95%
  • Children ≤5 years: ≥92%

Safer SABA Use

• Lower recommended SABA doses to minimize adverse effects, including SABA-induced lactic acidosis.

2. Treatment Strategy Updates

Track 1 (Preferred)

Anti-inflammatory Reliever Therapy

• As-needed low-dose ICS–formoterol remains the preferred reliever from Steps 1–4.
• Demonstrated benefits:
  • Fewer severe exacerbations
  • Reduced emergency visits
  • Better long-term control than SABA-only therapy.

Track 2 (Alternative)

• Step 1 now includes ICS–SABA (Anti-inflammatory Reliever Therapy).
• Based on BATURA trial evidence showing reduced risk of severe exacerbations compared with SABA alone.

3. Severe Asthma Updates

New Biologic

Depemokimab

• Ultra-long-acting anti-IL-5 monoclonal antibody
• Administration: Every 26 weeks
• Approved for:
  • Severe eosinophilic asthma (≥12 years)
  • Chronic rhinosinusitis with nasal polyps

New Biosimilar

• Omalizumab-igec
• First biosimilar anti-IgE therapy included in GINA.

Updated Treatment Algorithms

• Refined decision pathways for:
  • Biologic selection
  • LAMA add-on therapy
  • Triple inhaled therapy

4. Diagnosis & Practical Guidance

Bronchodilator Response

Positive reversibility test:

• Increase in FEV₁ or FVC
• ≥12% AND ≥200 mL from baseline (adults).

Biomarkers

Support diagnosis of Type 2 inflammation:

• Blood eosinophilia
• FeNO:
  • Adults: >50 ppb
  • Children: >35 ppb

Normal values do not exclude Type 2 asthma.

Inhaler Technique

New practical reminder:

• Shake all suspension pMDIs immediately before every actuation to ensure correct drug delivery.

New Assessment Tools

GINA now highlights:

• CAAT (Chronic Airways Assessment Test)  
• Peds-AIRQ (Pediatric Asthma Impairment and Risk Questionnaire) 

The Chronic Airways Assessment Test (CAAT)*

Slide Sets

Whats new in GINA 2026         

Download from Below Link :

Whats-new-in-GINA-2026-WEB (1)

GINA 2026 :  Severe Asthma 

Download from Below Link :

GINA-Severe-Asthma-Slides-2026-WEB 

Key Take-Home Messages

• ✅ ICS–formoterol remains the preferred reliever strategy.
• ✅ New standardized emergency management flowcharts improve consistency of care.
• ✅ Conservative SABA dosing enhances patient safety.
• ✅ Depemokimab expands treatment options for severe eosinophilic asthma.
• ✅ Biomarkers support—but do not replace—clinical diagnosis.
• ✅ Correct inhaler technique remains a cornerstone of effective asthma management.
• ✅ Global priority remains improving equitable access to inhaled corticosteroid-containing therapies.